MedTrace Logo

Duration of IPV Priming and Antibody Decay

NCT03202719 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1645

Last updated 2020-11-25

No results posted yet for this study

Summary

This is an open-label randomized phase IV clinical trial assessing immunogenicity of poliovirus vaccines.Participants will be enrolled at 6 weeks of age and followed to 18 months of age. The study will recruit 1645 participants in five arms.

Conditions

  • Poliomyelitis

Interventions

BIOLOGICAL

Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age

bOPV at 6, 10 and 14 weeks of age

BIOLOGICAL

Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age

IPV at 14 weeks and 18 months of age

BIOLOGICAL

Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age

IPV at 14 weeks, 18 weeks and 18 months of age

BIOLOGICAL

Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age

IPV at 14 weeks and 9 months of age

BIOLOGICAL

Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age

IPV at 6 weeks and 9 months of age

BIOLOGICAL

Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age

IPV at 6 and 14 weeks of age

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Weeks
Max Age
7 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-05
Primary Completion
2019-10-01
Completion
2019-10-01

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03202719 on ClinicalTrials.gov